OncoMatch/Clinical Trials/NCT06726564
A Study of MT027 in Patients with Pleural Malignant Tumors
Is NCT06726564 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MT027 cells suspension for advanced malignant solid tumor.
Treatment: MT027 cells suspension — This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy.. Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Mesothelioma
Biomarker criteria
Required: CD276 overexpression (positive for B7-H3 expression)
tumor cells in the pathological section of the primary lesion or malignant pleural effusion were positive for B7-H3 expression
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard treatment
the original pleural cavity malignant tumor after standard treatment failure, or top treatment
Cannot have received: B7-H3 CAR-T cell therapy
always had targeted B7 - H3 CAR - T cells treatment
Lab requirements
Blood counts
ANC ≥ 1.5×10^9/L; platelets ≥ 80×10^9/L; hemoglobin ≥ 80 g/L (transfusion/erythropoiesis agent allowed)
Kidney function
Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
Liver function
total bilirubin ≤ 2x ULN; AST and ALT ≤ 3x ULN (no liver metastasis) or ≤ 5x ULN (with liver metastasis)
Cardiac function
NYHA grade 3 or above excluded
Routine blood: ANC ≥1.5×10^9/L; platelets ≥80×10^9/L; hemoglobin ≥80 g/L. Liver: total bilirubin ≤2x ULN; AST/ALT ≤3x ULN (no liver mets) or ≤5x ULN (with liver mets). Kidney: serum creatinine ≤2x ULN or CrCl ≥50 mL/min. Cardiac: NYHA grade 3 or above excluded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify